Although the CD4+ TILs also remained stable in the combination group, the proliferation of CD4+ T cells, the Th1/Th2 ratio as well as IFNγ+ CD4+ TILs also increased, indicating an increase of tumor-specific CD4+ T cells by the combination treatment (Figure 2D). The gene discussed is CD4; the disease is neoplasm.